Solar Supply Chains: The U.S. Section 232 case on polysilicon is tightening again, with new minimum import prices and a 15% tariff on covered downstream solar products (wafers, cells, modules) set to start Dec. 4, 2026—Liechtenstein-linked trade may face higher costs depending on tariff caps. Healthcare & Biotech: The EU’s CHMP backed Merck’s perioperative KEYTRUDA plus Padcev for resectable muscle-invasive bladder cancer, with a final European Commission decision expected in Q4 2026; separately, Zealand Pharma won a positive CHMP opinion for Zeydovio (glepaglutide) for short bowel syndrome, a major Europe advance after more than a decade. EU–Canada Industrial Policy: EU Commission President Ursula von der Leyen proposed Canada as the bloc’s first “associate member,” a process still undefined in law but aimed at deeper cooperation in manufacturing, tech, defense industry, energy and critical minerals—Liechtenstein’s EEA position makes the debate especially relevant for regional market access. Digital Finance in the Region: Switzerland’s CA next bank went live with Avaloq’s new mobile banking app, using a SaaS model to expand payments and investment self-service—Avaloq also operates in Liechtenstein, keeping regional fintech momentum in view. Food Trade Pressure: Russia extended its Western fruit and vegetable import ban through Dec. 31, 2028, including products from Canada and Liechtenstein, adding another headwind for agricultural exporters. Patent Clash: Oxford Nanopore secured a Unified Patent Court injunction blocking MGI Tech’s CycloneSEQ sequencing systems across multiple European markets, including Liechtenstein.